Logo En IconLogo Mark IconIcelandic Intellectual Property Office
Plus Black IconMortgagePlus Black IconLicense

SPC427

Nirsevimab

  • Status:
    Veitt
  • Application date:
    28.4.2023
  • Application published:
    15.7.2023
  • Grant published:
    15.10.2024
  • Max expiry date:
    2.11.2037
  • Medicine name:
    Beyfortus
  • Medicine for children:
    No

Timeline

Today
28.4.2023Application
15.7.2023Publication
15.10.2024Registration
2.11.2037Expires

Marketing license

  • IS authorization number:
    EU1/22/1689/001-003; EU/1/22/1689/004-006
  • Date:
    18.11.2022
  • Foreign authorization number:
    EU/1/22/1689
  • Date:
    31.10.2022

Owner

  • Name:
    MedImmune Limited
  • Address:
    Milstein Building, Granta Park, Cambridge GB

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Deadlines

TypeDeadline until

Type: Frestur til að fara yfir drög að vottorði

Deadline until: 16.09.2024

Upload documents